GLOW Peptide: GHK-Cu, BPC-157, and TB-500 indexed against the published literature.

GLOW peptide is a three-peptide research blend combining GHK-Cu (glycyl-L-histidyl-L-lysine copper tripeptide), BPC-157 (a 15-amino-acid gastric-derived synthetic peptide), and TB-500 (a synthetic fragment of Thymosin Beta-4). Each constituent is studied separately in the published preclinical and clinical literature. No controlled trial has examined the combination as a single formulation ^[23].

GHK-Cu is an endogenous human tripeptide found in plasma, saliva, and urine. Plasma levels decline from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60 — a 60% reduction coinciding with measurable decline in skin regenerative capacity ^[1]. At nanomolar concentrations (1–10 nM), GHK-Cu stimulates collagen and glycosaminoglycan synthesis while modulating matrix metalloproteinase (MMP) and TIMP activity in dermal fibroblasts ^[2].

BPC-157 — Body Protective Compound 157 — is a 15-amino-acid synthetic pentadecapeptide derived from a protein in human gastric juice, with documented stability in gastric acid for more than 24 hours. In rodent wound models at doses of 10 µg/kg, 10 ng/kg, and 10 pg/kg, BPC-157 consistently accelerated wound re-epithelialization, reduced inflammatory infiltration, and improved collagen organization across incisional, excisional, burn, and diabetic ulcer models ^[13].

TB-500 is a synthetic fragment of Thymosin Beta-4, the major G-actin-sequestering molecule in eukaryotic cells. By maintaining a pool of unpolymerized actin, it enables rapid cytoskeletal reorganization during cell migration — a prerequisite for wound closure. Separately, TB-500 directly inhibits NF-kB RelA/p65 nuclear translocation, suppressing IL-8 and other pro-inflammatory cytokines independent of its actin-binding function ^[18]. Thymosin Beta-4, the parent protein, is the only GLOW constituent with Phase 2 human wound-healing trial data ^[20].

The combination rationale is mechanistic: GHK-Cu addresses collagen and ECM gene expression, BPC-157 addresses angiogenesis and fibroblast priming, and TB-500 enables cell migration and inflammatory resolution. Whether these mechanisms amplify each other in a combined protocol is a question without a published answer.

GLOW peptide targets three axes of skin and tissue repair studied extensively in preclinical models: collagen and extracellular-matrix (ECM) remodeling, vascular support and angiogenesis, and inflammatory resolution.

On the collagen axis: GHK-Cu at 1–10 nM upregulated collagen I, dermatan sulfate, chondroitin sulfate, and decorin in human dermal fibroblasts while simultaneously modulating MMP-2 activation with TIMP-1/TIMP-2 inhibition — balancing matrix synthesis and breakdown rather than simply accelerating either ^[2]. A randomized clinical trial (n=40 female volunteers, ages 40–65, 8 weeks) found GHK-Cu in a nano-carrier formulation reduced wrinkle volume by 55.8% (p<0.001) and wrinkle depth by 32.8% (p=0.012) vs control serum, with confirmed collagen and elastin upregulation ^[4].

On the vascular axis: BPC-157 promotes angiogenesis by upregulating VEGFR2 receptor expression — not VEGF-A itself — and activating the downstream VEGFR2-Akt-eNOS signaling cascade. This was demonstrated in CAM assay, tube formation assay, and rat hind-limb ischemia model, with enhanced blood flow recovery and vessel density vs controls ^[12].

On the inflammatory axis: TB-500's direct inhibition of NF-kB RelA/p65 nuclear translocation suppresses IL-8 and pro-inflammatory cytokines via a mechanism distinct from its actin-sequestering function ^[18]. GHK-Cu reinforces this via Nrf2 antioxidant pathway activation and NFkB suppression ^[6].

No study has measured the combined effect of all three acting simultaneously.

The GLOW blend has been studied — at the constituent level — for four primary research applications: collagen production and skin remodeling, wound healing and tissue repair, hair follicle cycling and growth, and anti-inflammatory signaling.

Skin remodeling is the most clinically evidenced application. GHK-Cu has produced statistically significant reductions in wrinkle depth and volume in multiple human clinical trials, and outperformed vitamin C (50%) and retinoic acid (40%) for procollagen synthesis in 70% of subjects in a one-month comparative study ^[5]. These are topical application results; injectable GHK-Cu has a separate, smaller evidence base.

Wound healing spans all three constituents. BPC-157 at picogram-level doses improved granulation tissue maturation and reduced inflammation in diabetic wound models, outperforming PDGF-BB/becaplermin in collagen organization ^[13]. Thymosin Beta-4 accelerated re-epithelialization 42–61% in rat full-thickness wound models and stimulated keratinocyte migration 2–3-fold in vitro at as little as 10 picograms ^[17].

Hair follicle research is primarily GHK-Cu and TB-500. GHK-Cu stimulated follicle size, upregulated VEGF and FGF, and produced visible growth indicators within 10 days of intradermal injection in a clinical study ^[8]. In a randomized, double-blind trial (n=45), a GHK complex increased hair count by 52.6–71.5 strands per group vs 9.6 for placebo (p<0.05) ^[9]. TB-500 (Thymosin Beta-4) doubled follicle growth in rats within 7 days of topical application ^[19].

The GLOW peptide dosage and GLOW peptide benefits pages cover each application category in greater depth.

The theoretical rationale for combining GHK-Cu, BPC-157, and TB-500 is that each addresses a different rate-limiting step in cutaneous repair. GHK-Cu signals fibroblasts to reset gene expression toward a younger, more repair-competent profile — affecting approximately 31.2% of all human genes, with 59% upregulated and 41% suppressed ^[3]. BPC-157 ensures the vascular supply: VEGFR2 upregulation drives angiogenesis that delivers oxygen and nutrients to healing tissue ^[12]. TB-500 enables the cellular workforce: G-actin sequestration frees the cytoskeletal machinery that keratinocytes and fibroblasts need to migrate into a wound site ^[21].

The sequence matters in healing models. Angiogenesis (BPC-157) precedes matrix synthesis (GHK-Cu); cell migration (TB-500) enables re-epithelialization before collagen remodeling can complete. A protocol that addresses all three in parallel is conceptually coherent. Controlled evidence for the specific combination does not exist.

The research literature overview covers each constituent's mechanistic data with full citations. The GHK-Cu copper peptide mechanism section details the gene-expression and fibroblast-signaling data in full.

GHK-Cu is glycyl-L-histidyl-L-lysine copper(II) — a three-amino-acid tripeptide (MW ~315 Da as free peptide) that forms a high-affinity complex with copper(II) ions. It is an endogenous human peptide found in plasma at ~200 ng/mL at age 20, declining to ~80 ng/mL by age 60 ^[1]. GHK-Cu for topical cosmetic use has a documented safety record spanning decades. Injectable GHK-Cu lacks a comparable human safety dataset.

BPC-157 — Body Protective Compound 157 — is a 15-amino-acid synthetic peptide (sequence: GEPPPGKPADDAGLV, MW 1,419 Da) derived from a protein found in human gastric juice ^[25]. It is stable in gastric acid for more than 24 hours and has been studied via intraperitoneal, oral, topical, and subcutaneous routes in animal models. BPC-157 was classified as an FDA Category 2 bulk drug substance in September 2023, barring its use in compounded medications in the United States. WADA added it to the S0 Non-Approved Substances list in 2022 ^[22].

TB-500 is a synthetic peptide fragment corresponding to residues 17–23 of Thymosin Beta-4, a 43-amino-acid protein abundant in platelets and wound-site fluids. TB-500 is prohibited by WADA under S2.3 Growth Factors and Growth Factor Modulators (effective January 2012). It is not FDA-approved for any human clinical indication ^[23].

What Is GLOW 70? GLOW 70 is a 70 mg vial format of the GLOW blend, a pre-measured compounded formulation combining GHK-Cu, BPC-157, and TB-500 in a single vial per clinic protocol documentation. Clinic documentation describes reconstitution with 3 mL of bacteriostatic water, yielding approximately 23 mg/mL total peptide concentration for dosing calculations. No peer-reviewed publication has validated this vial format or its specific component ratios.